SCHEMBL2497215

SCHEMBL2497215

CCCOC(N)OCCC

nearest known ligand 0.34

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
DNM1 Q05193 1/20 0.32
HSD17B10 Q99714 1/20 0.32
ADRB2 P07550 1/20 0.32
ADRB1 P08588 1/20 0.32
ADRB3 P13945 1/20 0.32
TDP1 Q9NUW8 1/20 0.31
THRB P10828 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8412922 0.81 ADRB2 (0.48) CA1CA2DNM1ADRB2ADRB1
SCHEMBL309239 0.78
SCHEMBL8076684 0.75
SCHEMBL19442182 0.75
SCHEMBL308837 0.75
SCHEMBL27605114 0.75 ADRB2 (0.42) CA1CA2DNM1ADRB2ADRB1
SCHEMBL577776 0.73 TSHR (0.39)
SCHEMBL21026920 0.73
SCHEMBL22268437 0.73
SCHEMBL308919 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4276095-A2 PROCESSES FOR PREPARING ASK1 INHIBITORS Gilead Sciences, Inc. (US) 2023-11-15 EP disclosed
EP-3693366-B1 PROCESSES FOR PREPARING ASK1 INHIBITORS GILEAD SCIENCES INC (US) 2023-06-28 EP disclosed
US-20220135527-A1 PROCESSES FOR PREPARING ASK1 INHIBITORS GILEAD SCIENCES, INC. 2022-05-05 US disclosed
US-11261161-B2 Processes for preparing ASK1 inhibitors GILEAD SCIENCES, INC. (US) 2022-03-01 US disclosed
EP-3237404-B1 PROCESSES FOR PREPARING ASK1 INHIBITORS GILEAD SCIENCES INC (US) 2020-11-11 EP disclosed
US-20200283393-A1 PROCESSES FOR PREPARING ASK1 INHIBITORS GILEAD SCIENCES, INC. 2020-09-10 US disclosed
EP-3693366-A1 PROCESSES FOR PREPARING ASK1 INHIBITORS Gilead Sciences, Inc. (US) 2020-08-12 EP disclosed
US-10604490-B2 Processes for preparing ASK1 inhibitors GILEAD SCIENCES, INC. (US) 2020-03-31 US disclosed
US-20180022708-A1 PROCESSES FOR PREPARING ASK1 INHIBITORS GILEAD SCIENCES, INC. 2018-01-25 US disclosed
EP-2072496-B1 METHOD FOR PRODUCING HIGH-PURITY QUATERNARY AMMONIUM SALT OTSUKA CHEMICAL CO LTD (JP) 2017-11-15 EP disclosed
US-8029690-B2 Process for production of highly pure quaternary ammonium salt OTSUKA CHEMICAL CO., LTD. (JP) 2011-10-04 US disclosed
US-20100044617-A1 Method for producing high-purity quaternary ammonium salt STELLA CHEMIFA CORPORATION (JP) 2010-02-25 US disclosed
US-20090272933-A1 Process for production of highly pure quaternary ammonium salt STELLA CHEMIFA CORPORATION (JP) 2009-11-05 US disclosed
EP-2098518-A1 PROCESS FOR PRODUCTION OF HIGHLY PURE QUATERNARY AMMONIUM SALT Otsuka Chemical Co., Ltd. (JP) 2009-09-09 EP disclosed
EP-2072496-A1 METHOD FOR PRODUCING HIGH-PURITY QUATERNARY AMMONIUM SALT Otsuka Chemical Co., Ltd. (JP) 2009-06-24 EP disclosed
CN-101353341-A Colorant reacted by oxyalkylene-substituted aminophenol intermediate MILLIKEN & CO (US) 2009-01-28 CN disclosed
CN-100424135-C Colorants produced by reaction of oxyalkylene-substituted aminophenol intermediate MILLIKEN & CO (US) 2008-10-08 CN disclosed
CN-1847322-A Colorants produced by reaction of oxyalkylene-substituted aminophenol intermediate MILLIKEN & CO (US) 2006-10-18 CN disclosed
CN-1263728-C Oxyalkylene-substituted aminophenol intermediates MILLIKEN & CO (US) 2006-07-12 CN disclosed
CN-1351583-A Oxyalkylene-substituted aminophenol intermediates MILLIKEN & CO (US) 2002-05-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200283393-A1 PROCESSES FOR PREPARING ASK1 INHIBITORS MAP3K1, MAP3K6, MAP3K7 CA1 4790/4885CA2 4680/4885DNM1 1048/4885
US-10604490-B2 Processes for preparing ASK1 inhibitors MAP3K1, MAP3K6, MAP3K7 CA1 4790/4885CA2 4680/4885DNM1 1048/4885
US-11261161-B2 Processes for preparing ASK1 inhibitors MAP3K1, MAP3K6, MAP3K7 CA1 4790/4885CA2 4680/4885DNM1 1048/4885
US-20180022708-A1 PROCESSES FOR PREPARING ASK1 INHIBITORS MAP3K1, MAP3K6, MAP3K7 CA1 4790/4885CA2 4680/4885DNM1 1048/4885
US-20220135527-A1 PROCESSES FOR PREPARING ASK1 INHIBITORS MAP3K1, MAP3K6, MAP3K7 CA1 4790/4885CA2 4680/4885DNM1 1048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.